AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27130222 — intervention group
Group type: EXPERIMENTAL
Intervention: hypothermia
Number of subjects: 0
Study 27130222 — intervention group
Group type: EXPERIMENTAL
Intervention: glial scar degradation
Number of subjects: 0
Study 27130222 — intervention group
Group type: EXPERIMENTAL
Intervention: Rho-ROCK inhibition
Number of subjects: 0
Study 27130222 — intervention group
Group type: EXPERIMENTAL
Intervention: cell-based therapies
Number of subjects: 0
Study 27130222 — intervention group
Group type: EXPERIMENTAL
Intervention: novel bioengineered adjuncts
Number of subjects: 0
Study 27130348 — intervention group
Group type: EXPERIMENTAL
Intervention: RLP cholesterol (RLP-C) levels
Number of subjects: 4932
Study 27130348 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate-density lipoprotein cholesterol
Number of subjects: 4932
Study 27130468 — intervention group
Group type: EXPERIMENTAL
Intervention: Crizotinib
Number of subjects: 59
Study 27130468 — intervention group
Group type: EXPERIMENTAL
Intervention: Alectinib
Number of subjects: 59
Study 27130468 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceritinib
Number of subjects: 59
Study 27130637 — intervention group
Group type: EXPERIMENTAL
Intervention: EMST
Number of subjects: 14
Study 27132698 — intervention group
Group type: EXPERIMENTAL
Intervention: Idiopathic thrombotic thrombocytopenic purpura (TTP)
Number of subjects: 939
Study 27132698 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-idiopathic thrombotic thrombocytopenic purpura (TTP)
Number of subjects: 939
Study 27132698 — intervention group
Group type: EXPERIMENTAL
Intervention: Autoimmune disease with anti-ADAMTS13 IgG
Number of subjects: 939
Study 27132698 — intervention group
Group type: EXPERIMENTAL
Intervention: Acquired disease of unknown cause
Number of subjects: 939
Study 27132698 — intervention group
Group type: EXPERIMENTAL
Intervention: Inherited disease (Upshaw-Schulman syndrome)
Number of subjects: 939
Study 27132698 — intervention group
Group type: EXPERIMENTAL
Intervention: Obstetrical thrombotic thrombocytopenic purpura
Number of subjects: 939
Study 27133597 — intervention group
Group type: EXPERIMENTAL
Intervention: Ex vivo expanded CD4(+)CD127(lo/-)CD25(+) regulatory T cells
Number of subjects: 0
Study 27133664 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide (10 mcg b.i.d.)
Number of subjects: 10
Study 27133759 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintedanib 200mg BID daily in a 4-week cycle until progression or intolerable toxicity
Number of subjects: 24
Study 27133823 — intervention group
Group type: EXPERIMENTAL
Intervention: Recurrent immunophenotype at diagnosis
Number of subjects: 0
Study 27134280 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab treatment
Number of subjects: 0
Study 27135612 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral vinorelbine (40 mg/m2 on day 1 and 8) with erlotinib (100 mg daily) in the CSV group (N = 16)
Number of subjects: 30
Study 27135612 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral vinorelbine (100 mg/week) with erlotinib (100 mg daily) in the MSV group (N = 14)
Number of subjects: 30
Study 27135612 — intervention group
Group type: COMPARATOR
Intervention: Vinorelbine co-administration in the CSV group
Number of subjects: 30
Study 27135612 — intervention group
Group type: COMPARATOR
Intervention: Vinorelbine co-administration in the MSV group
Number of subjects: 30
Study 27135792 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher intake of dessert foods
Number of subjects: 146
Study 27135792 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher intake of packaged snack foods
Number of subjects: 146
Study 27136388 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss at the end of the competition
Number of subjects: 14
Study 27136388 — intervention group
Group type: EXPERIMENTAL
Intervention: Resting metabolic rate (RMR) at the end of the competition
Number of subjects: 14
Study 27136388 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight regain after 6 years
Number of subjects: 14
Study 27136388 — intervention group
Group type: EXPERIMENTAL
Intervention: RMR after 6 years
Number of subjects: 14
Study 27136388 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolic adaptation after 6 years
Number of subjects: 14
Study 27136388 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between weight regain and metabolic adaptation
Number of subjects: 14
Study 27136388 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between weight loss maintenance and metabolic slowing
Number of subjects: 14
Study 27136905 — intervention group
Group type: EXPERIMENTAL
Intervention: Migalastat HCl 150 mg (single oral dose)
Number of subjects: 32
Study 27136910 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral canagliflozin 300 mg
Number of subjects: 9
Study 27136910 — intervention group
Group type: COMPARATOR
Intervention: Intravenous [(14) C]-canagliflozin 10 µg
Number of subjects: 9
Study 27136910 — intervention group
Group type: COMPARATOR
Intervention: Total [(14) C] radioactivity
Number of subjects: 9
Study 27136910 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall assessment
Number of subjects: 9
Study 27137149 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg once daily on days 1 and 6, twice daily on days 2-5
Number of subjects: 12
Study 27137427 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram, sertraline, or venlafaxine extended-release, open-label treatment for 8 weeks
Number of subjects: 157
Study 27137427 — intervention group
Group type: EXPERIMENTAL
Intervention: DTI-derived metric (ratio of fractional anisotropy of the stria terminalis over the CgC)
Number of subjects: 157
Study 27137427 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram and sertraline
Number of subjects: 157
Study 27138005 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-infected adults
Number of subjects: 500
Study 27138005 — intervention group
Group type: COMPARATOR
Intervention: HIV-uninfected controls
Number of subjects: 500
Study 27138005 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-infected adults after MMR vaccination
Number of subjects: 500
Study 27138005 — intervention group
Group type: COMPARATOR
Intervention: HIV-uninfected controls after MMR vaccination
Number of subjects: 500
Study 27138015 — intervention group
Group type: EXPERIMENTAL
Intervention: Enobosarm 3 mg orally once daily for 147 days
Number of subjects: 300
Study 27138015 — intervention group
Group type: COMPARATOR
Intervention: Placebo orally once daily for 147 days
Number of subjects: 300
Study 27138015 — intervention group
Group type: EXPERIMENTAL
Intervention: Enobosarm 3 mg
Number of subjects: 300
Study 27138015 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study 27138015 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 300
Study 27138310 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin K antagonists (VKAs)
Number of subjects: 7835
Study 27138310 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-Vitamin K antagonist oral anticoagulants (NOAC)
Number of subjects: 7835
Study 27138310 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiplatelet agents
Number of subjects: 7835
Study 27138310 — intervention group
Group type: EXPERIMENTAL
Intervention: Rate/rhythm control strategies
Number of subjects: 7835
Study 27138582 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (10 mg/kg every 2 weeks)
Number of subjects: 32
Study 27138601 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB) surgery
Number of subjects: 7
Study 27138628 — intervention group
Group type: EXPERIMENTAL
Intervention: Leucine supplementation at varying doses (50 to 750 mg kg(-1) day(-1))
Number of subjects: 6
Study 27139036 — intervention group
Group type: EXPERIMENTAL
Intervention: Cixutumumab 6 mg/kg q2w
Number of subjects: 21
Study 27139036 — intervention group
Group type: EXPERIMENTAL
Intervention: Cixutumumab 10 mg/kg q2w
Number of subjects: 21
Study 27139036 — intervention group
Group type: EXPERIMENTAL
Intervention: Cixutumumab 15 mg/kg q3w
Number of subjects: 21
Study 27139036 — intervention group
Group type: EXPERIMENTAL
Intervention: Cixutumumab 20 mg/kg q3w
Number of subjects: 21
Study 27139473 — intervention group
Group type: EXPERIMENTAL
Intervention: β-lactam/β-lactamase inhibitor (BLBLI) combinations in the empirical-therapy cohort (ETC)
Number of subjects: 627
Study 27139473 — intervention group
Group type: COMPARATOR
Intervention: Carbapenems in the empirical-therapy cohort (ETC)
Number of subjects: 627
Study 27139473 — intervention group
Group type: EXPERIMENTAL
Intervention: β-lactam/β-lactamase inhibitor (BLBLI) combinations in the targeted-therapy cohort (TTC)
Number of subjects: 627
Study 27139473 — intervention group
Group type: COMPARATOR
Intervention: Carbapenems in the targeted-therapy cohort (TTC)
Number of subjects: 627
Study 27139805 — intervention group
Group type: EXPERIMENTAL
Intervention: Investigational trivalent GBS vaccine (20 μg dose, two injections, 1 month apart)
Number of subjects: 380
Study 27139805 — intervention group
Group type: EXPERIMENTAL
Intervention: Investigational trivalent GBS vaccine (0.5 μg, 2.5 μg, or 5.0 μg doses, one injection at 28-35 weeks' gestation)
Number of subjects: 380
Study 27139805 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 380
Study 27139805 — intervention group
Group type: EXPERIMENTAL
Intervention: Investigational trivalent GBS vaccine (various doses)
Number of subjects: 380
Study 27140229 — intervention group
Group type: EXPERIMENTAL
Intervention: Faldaprevir 120 mg once daily with deleobuvir 800 mg twice daily (b.i.d.) and weight-based ribavirin for 24 weeks
Number of subjects: 51
Study 27140229 — intervention group
Group type: EXPERIMENTAL
Intervention: Faldaprevir 120 mg once daily with deleobuvir 600 mg three times daily (t.i.d.) and weight-based ribavirin for 24 weeks
Number of subjects: 51
Study 27140401 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous iron infusion
Number of subjects: 13
Study 27140401 — intervention group
Group type: COMPARATOR
Intervention: Control group (iron-replete)
Number of subjects: 13
Study 27140401 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxic exposure (first 6-hour period)
Number of subjects: 13
Study 27140401 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum erythropoietin responses to hypoxia
Number of subjects: 13
Study 27140518 — intervention group
Group type: EXPERIMENTAL
Intervention: Facial VCA procurement
Number of subjects: 35
Study 27140533 — intervention group
Group type: EXPERIMENTAL
Intervention: Human milk (HM) from obese mothers
Number of subjects: 30
Study 27140533 — intervention group
Group type: EXPERIMENTAL
Intervention: Human milk insulin
Number of subjects: 30
Study 27140533 — intervention group
Group type: EXPERIMENTAL
Intervention: Human milk leptin and insulin
Number of subjects: 30
Study 27140803 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 200 mg/day with glyburide 1.25 mg/day
Number of subjects: 0
Study 27140803 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 300 mg/day with metformin 2000 mg/day
Number of subjects: 0
Study 27140803 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 300 mg/day with simvastatin 40 mg/day
Number of subjects: 0
Study 27141828 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium
Number of subjects: 5992
Study 27141828 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5992
Study 27142174 — intervention group
Group type: EXPERIMENTAL
Intervention: Guideline-indicated care (including dietary advice, smoking cessation advice, P2Y12 inhibitors, coronary angiography)
Number of subjects: 389057
Study 27142174 — intervention group
Group type: EXPERIMENTAL
Intervention: Missed interventions (coronary angiography, cardiac rehabilitation, smoking cessation advice, statins)
Number of subjects: 389057
Study 27142184 — intervention group
Group type: EXPERIMENTAL
Intervention: Autofluorescence bronchoscopy (AFB) in addition to low-dose CT (LDCT) scan
Number of subjects: 333
Study 27142184 — intervention group
Group type: COMPARATOR
Intervention: Low-dose CT (LDCT) scan
Number of subjects: 333
Study 27142184 — intervention group
Group type: COMPARATOR
Intervention: AFB alone
Number of subjects: 333
Study 27142313 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram for predicting regression to normoglycaemia based on non-invasive variables.
Number of subjects: 1197
Study 27142313 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram model validation.
Number of subjects: 1197
Study 27142472 — intervention group
Group type: EXPERIMENTAL
Intervention: Arsenic trioxide (ASO) administered as an intravenous infusion over 1-2 hours daily for 4 days in week 1 and for 2 days in weeks 2-6 of an 8-week cycle.
Number of subjects: 17
Study 27142472 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin (3 mg/kg i.p. weekly) tested in PDX derived from platinum-sensitive SCLC.
Number of subjects: 17
Study 27142472 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin (3 mg/kg i.p. weekly) tested in PDX derived from platinum-refractory SCLC.
Number of subjects: 17
Study 27142472 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-derived xenografts (PDX) grown from transplanted biopsy samples.
Number of subjects: 17
Study 27142472 — intervention group
Group type: EXPERIMENTAL
Intervention: Arsenic trioxide (ASO) in vitro efficacy.
Number of subjects: 17
Study 27142672 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypocaloric hyperproteic diet (HHD), ~1000 kcal/day, ~125 g protein/day for 3 weeks
Number of subjects: 15
Study 27143353 — intervention group
Group type: EXPERIMENTAL
Intervention: Leptin antagonist applied locally to the ascending aorta in AngII-infused mice.
Number of subjects: 0
Study 27143353 — intervention group
Group type: COMPARATOR
Intervention: Exogenous leptin applied on the surface of the ascending aorta.
Number of subjects: 0
Study 27143668 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-1-infected individuals
Number of subjects: 527
Study 27143668 — intervention group
Group type: COMPARATOR
Intervention: HIV-negative controls
Number of subjects: 527
Study 27143668 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-1-infected individuals with prior stavudine exposure
Number of subjects: 527
Study 27143789 — intervention group
Group type: EXPERIMENTAL
Intervention: Anakinra
Number of subjects: 43
Study 27144169 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm crank ergometry (ACE)
Number of subjects: 12
Study 27144169 — intervention group
Group type: COMPARATOR
Intervention: Wheelchair ergometry (WCE)
Number of subjects: 12
Study 27145169 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency abdominal surgery in high-HDI countries
Number of subjects: 10745
Study 27145169 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency abdominal surgery in middle-HDI countries
Number of subjects: 10745
Study 27145169 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency abdominal surgery in low-HDI countries
Number of subjects: 10745
Study 27145169 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of surgical safety checklist in low- and middle-income countries
Number of subjects: 10745
Study 27145169 — intervention group
Group type: COMPARATOR
Intervention: Emergency abdominal surgery in middle-income countries
Number of subjects: 10745
Study 27145169 — intervention group
Group type: COMPARATOR
Intervention: Emergency abdominal surgery in low-income countries
Number of subjects: 10745
Study 27145310 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptomatic treatment (nonantibiotic) consisting of mild analgesics (nonsteroidal anti-inflammatory drug or paracetamol)
Number of subjects: 161
Study 27145310 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptomatic treatment (nonantibiotic)
Number of subjects: 161
Study 27145749 — intervention group
Group type: EXPERIMENTAL
Intervention: EWA algorithm (Expectation Maximization, weighted intensity, a priori information)
Number of subjects: 124
Study 27145999 — intervention group
Group type: EXPERIMENTAL
Intervention: Hib-MenC-TT vaccine coadministered with DTPa-based combination vaccines and pneumococcal conjugate vaccine.
Number of subjects: 530
Study 27145999 — intervention group
Group type: COMPARATOR
Intervention: Control MenC conjugate vaccine coadministered with DTPa-based combination vaccines and pneumococcal conjugate vaccine.
Number of subjects: 530
Study 27145999 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (including both Hib-MenC-TT and control)
Number of subjects: 530
Study 27146407 — intervention group
Group type: EXPERIMENTAL
Intervention: Unacylated ghrelin (UAG) levels in infants with PWS
Number of subjects: 37
Study 27146407 — intervention group
Group type: EXPERIMENTAL
Intervention: Acylated ghrelin (AG) levels in infants with PWS
Number of subjects: 37
Study 27146407 — intervention group
Group type: EXPERIMENTAL
Intervention: AG/UAG ratio in infants with PWS
Number of subjects: 37
Study 27146407 — intervention group
Group type: COMPARATOR
Intervention: Control group (age-matched controls without endocrine disorder)
Number of subjects: 37
Study 27146511 — intervention group
Group type: EXPERIMENTAL
Intervention: Genomic information in the anger condition
Number of subjects: 190
Study 27146511 — intervention group
Group type: EXPERIMENTAL
Intervention: Genomic information
Number of subjects: 190
Study 27146652 — intervention group
Group type: EXPERIMENTAL
Intervention: COPD patients
Number of subjects: 23
Study 27146652 — intervention group
Group type: COMPARATOR
Intervention: Healthy older adults (control group)
Number of subjects: 23
Study 27146701 — intervention group
Group type: EXPERIMENTAL
Intervention: Implants (10,096 total)
Number of subjects: 2670
Study 27146701 — intervention group
Group type: COMPARATOR
Intervention: Smoking
Number of subjects: 2670
Study 27146701 — intervention group
Group type: COMPARATOR
Intervention: Antidepressants intake
Number of subjects: 2670
Study 27146799 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide Once Weekly (QW)
Number of subjects: 129
Study 27147390 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical prediction rule based on ECG, BNP levels, and other biomarkers
Number of subjects: 1959
Study 27147390 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up of patients' cohort
Number of subjects: 1959
Study 27147615 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported sexual abstinence
Number of subjects: 715
Study 27147615 — intervention group
Group type: EXPERIMENTAL
Intervention: Item non-response regarding sexual behaviour
Number of subjects: 715
Study 27147615 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported abstinence with item non-response
Number of subjects: 715
Study 27147905 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led patient education program
Number of subjects: 26
Study 27147905 — intervention group
Group type: COMPARATOR
Intervention: Control group (no education)
Number of subjects: 26
Study 27148068 — intervention group
Group type: EXPERIMENTAL
Intervention: BAT+ group
Number of subjects: 18
Study 27148134 — intervention group
Group type: EXPERIMENTAL
Intervention: Eye Movement Desensitization and Reprocessing (EMDR)
Number of subjects: 42
Study 27148134 — intervention group
Group type: COMPARATOR
Intervention: Relaxation Therapy (RT)
Number of subjects: 42
Study 27148452 — intervention group
Group type: EXPERIMENTAL
Intervention: CC-486 (300 mg once daily for the first 21 days of 28-day treatment cycles)
Number of subjects: 0
Study 27148452 — intervention group
Group type: COMPARATOR
Intervention: Placebo (once daily for the first 21 days of 28-day treatment cycles)
Number of subjects: 0
Study 27148765 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean Daytime Activity (MDTA)
Number of subjects: 79
Study 27148765 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep Quality (PSQI)
Number of subjects: 79
Study 27148765 — intervention group
Group type: EXPERIMENTAL
Intervention: FACIT-F
Number of subjects: 79
Study 27148765 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall Survival (OS)
Number of subjects: 79
Study 27149114 — intervention group
Group type: EXPERIMENTAL
Intervention: PPV23 (23-valent pneumococcal polysaccharide vaccine) administered intramuscularly as a single dose
Number of subjects: 100
Study 27149252 — intervention group
Group type: EXPERIMENTAL
Intervention: E1 (previously calculated equation for estimating fat-free mass)
Number of subjects: 155
Study 27149252 — intervention group
Group type: EXPERIMENTAL
Intervention: New predictive equation
Number of subjects: 155
Study 27149268 — intervention group
Group type: EXPERIMENTAL
Intervention: eABR measurements with stimulation by a single electrode at 70% of the dynamic range, followed by a summation of these four eABRs
Number of subjects: 16
Study 27149268 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurement of a single eABR with stimulation from all four electrodes at 70% of the dynamic range
Number of subjects: 16
Study 27149298 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceritinib
Number of subjects: 0
Study 27149635 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with PAD during pain-free walking
Number of subjects: 61
Study 27149635 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (nondisabled age-matched)
Number of subjects: 61
Study 27149955 — intervention group
Group type: EXPERIMENTAL
Intervention: CFS patients
Number of subjects: 120
Study 27149955 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 120
Study 27150464 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium monotherapy
Number of subjects: 700
Study 27150464 — intervention group
Group type: COMPARATOR
Intervention: Valproic acid (VPA) or treatment as usual (TAU)
Number of subjects: 700
Study 27150686 — intervention group
Group type: EXPERIMENTAL
Intervention: H2 receptor antagonists (H2RAs) used by 313 participants
Number of subjects: 6378
Study 27150686 — intervention group
Group type: EXPERIMENTAL
Intervention: H2 receptor antagonists (H2RAs)
Number of subjects: 6378
Study 27150686 — intervention group
Group type: COMPARATOR
Intervention: Non-use of H2 receptor antagonists (H2RAs)
Number of subjects: 6378
Study 27150693 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran Etexilate
Number of subjects: 0
Study 27150693 — intervention group
Group type: EXPERIMENTAL
Intervention: Idarucizumab
Number of subjects: 0
Study 27150693 — intervention group
Group type: EXPERIMENTAL
Intervention: Redosing Idarucizumab
Number of subjects: 0
Study 27151157 — intervention group
Group type: COMPARATOR
Intervention: TAS-102
Number of subjects: 30
Study 27151347 — intervention group
Group type: EXPERIMENTAL
Intervention: Biventricular pacing
Number of subjects: 0
Study 27151347 — intervention group
Group type: COMPARATOR
Intervention: Right ventricular pacing
Number of subjects: 0
Study 27151607 — intervention group
Group type: EXPERIMENTAL
Intervention: Edwards Sapien
Number of subjects: 848
Study 27151607 — intervention group
Group type: EXPERIMENTAL
Intervention: Medtronic CoreValve
Number of subjects: 848